Jimmie Hofman

CBO at Vicore Pharma

Speaker

Jimmie Hofman is an experienced dealmaker in the life sciences industry, with deep expertise in business development and corporate strategy. As Chief Business Officer at Vicore Pharma, he leads business development and partnering strategy as the company advances buloxibutid, its first-in-class oral AT2 receptor agonist for idiopathic pulmonary fibrosis, currently in the global Phase 2b ASPIRE trial.

Prior to joining Vicore in 2024, Jimmie was Senior Director, Business Development at Pieris Pharmaceuticals, where he helped secure strategic partnerships worth over $400 million in upfront and near-term payments and more than $6 billion in total milestone potential, with companies including AstraZeneca, Roche/Genentech, Seagen, Servier, and Boston Pharmaceuticals.